Loading, Please Wait...
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today provided a corporate update and reported financial results for the quarter ended September 30, 2019.
“I am very pleased with the progress we have made in a short period of time. While we leveraged the research from Pfizer to launch Allogene, we have built the company from the ground up. In parallel, we have initiated the build-out of in-house manufacturing capabilities, successfully progressed AlloCAR T programs into Phase 1 clinical development while creating next generation therapies and entering into agreements that will keep us at the forefront of cell therapy,” said David Chang, M.D., Ph.D., President, CEO and Co-Founder of Allogene Therapeutics. “With the initiation of our ALLO-715 Phase I UNIVERSAL trial in multiple myeloma, we have achieved all of the clinical goals that we set out for ourselves at the beginning of 2019. I am very proud of our team’s accomplishments and firmly believe that the time and investment Allogene is making in research, next generation technologies, manufacturing and personnel will provide us with the key building blocks needed to support our goal of being the first to bring an AlloCAR T therapy to patients.”
Pipeline Highlights
ALLO-501 (anti-CD19 AlloCAR T)
ALLO-715 (anti-BCMA AlloCAR T)
Additional Pipeline Updates
Corporate Highlights
Third Quarter Financial Results
Conference Call and Webcast Details
Allogene will host a live conference call and webcast today at 5:30 AM Pacific Time/8:30 AM Eastern Time to discuss financial results and provide a business update. To access the live conference call by telephone, please dial 1 (866) 940-5062 (U.S.) or 1 (409) 216-0618 (International). The conference ID number for the live call is 2747063. The webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and ability to progress the ALLO-501 ALPHA trial and ALLO-715 UNIVERSAL trial, the timing and Servier’s ability to progress the CALM and PALL trials to potential registrational trials, the ability to manufacture AlloCAR T™ therapies, the ability to initiate and progress additional clinical trials of AlloCAR T™ therapies, the potential benefits of AlloCAR T™ therapy and the 2019 financial guidance. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-Q for the quarter ended June 30, 2019. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
ALLOGENE THERAPEUTICS, INC.
SELECTED FINANCIAL DATA
(unaudited; in thousands, except share and per share data)
STATEMENTS OF OPERATIONS
Three Months Ended September 30, |
Nine Months Ended September 30, |
||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||
Operating expenses: | |||||||||||||||
Research and development | $ | 39,995 | $ | 10,870 | $ | 95,172 | $ | 133,356 | |||||||
General and administrative | 15,016 | 11,317 | 42,261 | 26,440 | |||||||||||
Total operating expenses | 55,011 | 22,187 | 137,433 | 159,796 | |||||||||||
Loss from operations | (55,011 | ) | (22,187 | ) | (137,433 | ) | (159,796 | ) | |||||||
Other income (expense), net: | |||||||||||||||
Change in fair value of convertible note payable | — | (19,415 | ) | — | (19,415 | ) | |||||||||
Interest expense | — | (3,358 | ) | — | (3,358 | ) | |||||||||
Interest and other income, net | 4,309 | 1,463 | 13,693 | 1,573 | |||||||||||
Loss before income taxes | (50,702 | ) | (43,497 | ) | (123,740 | ) | (180,996 | ) | |||||||
Benefit (expense) from income taxes | (33 | ) | — | 176 | — | ||||||||||
Net loss | (50,735 | ) | (43,497 | ) | (123,564 | ) | (180,996 | ) | |||||||
Net loss per share, basic and diluted | $ | (0.50 | ) | $ | (10.71 | ) | $ | (1.24 | ) | $ | (16.38 | ) | |||
Weighted-average number of shares used in computing net loss per share, basic and diluted | 102,186,644 | 4,060,419 | 99,801,001 | 11,048,451 |
SELECTED BALANCE SHEET DATA
As of September 30, 2019 |
As of December 31, 2018 |
||||||
Cash, cash equivalents and investments | $ | 601,946 | $ | 721,350 | |||
Total assets | 695,544 | 773,855 | |||||
Total liabilities | 75,828 | 70,691 | |||||
Total stockholders’ equity | 619,716 | 703,164 |
Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com